News Release(2024)

December 23, 2024

Regarding the approval of the additional indication for endometriosis in Europe for the GnRH antagonist YSELTY® (generic name linzagolix)

November 6, 2024

Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System (ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares

November 5, 2024

Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) and the Cancellation of Treasury Shares

October 16, 2024

Kissei Introduces Analysis and Preparative Purification Platform for Small Molecules

September 24, 2024

Succession of Manufacturing and Marketing Authorization for MARIZEV®, Diabetes Treatment

September 17, 2024

Launch of YSELTY® (generic name linzagolix) for uterine fibroid treatment in Europe

September 9, 2024

Drug discovery research collaboration agreement with Reborna Biosciences, Inc.

September 4, 2024

Licensing Agreement for "olutasidenib", an Acute Myeloid Leukemia Drug

July 16, 2024

Results of a Japan Phase III Clinical Trial of the GnRH Antagonist Linzagolix in Patients with Uterine Fibroids - Primary Endpoint has been Achieved -

June 10, 2024

Licensing Agreement for GnRH Antagonist Linzagolix with JW Pharmaceutical Corporation in Korea

March 19, 2024

Notice Concerning Status of Acquisition and Completion of the Company's Own Shares

March 1, 2024

Notice Concerning Status of Acquisition of the Company's Own Shares

February 1, 2024

Notice Concerning Status of Acquisition of the Company's Own Shares

January 4, 2024

Notice Concerning Status of Acquisition of the Company's Own Shares